Cresset and Redx Pharma announced
that they have signed a major drug discovery collaboration. The collaboration
gives Redx Pharma access to Cresset’s computational chemistry technologies for
use on their portfolio of drug discovery programs. In addition Cresset will
provide consulting services in the area of candidate selection across a broad
range of therapeutic areas and targets.
Rob Scoffin, CEO of Cresset says, “Cresset has developed an extensive range of consulting services around the
critical areas of library design, compound design, virtual screening, and lead
optimization. In this case we will initially be focussing our skills on helping
Redx with their lead candidate selection process, whilst the collaboration also
gives Redx the ability to access our expertise, in a very flexible manner,
across the full range of computational drug discovery services.”
The Redx programs make use of a
number of Cresset’s computational chemistry tools. In particular FieldTemplater
and FieldAlign are used respectively to provide binding hypotheses and
predictions of likely biological similarity for sets of molecules in various
lead series.
Cresset Group Ltd.,
www.cresset-group.com